- Solid Q3 results are coming for Johnson & Johnson (JNJ), says Bernstein, reiterating its Buy rating and $97 price target. OTC sales are expected to have grown 8%, says the team, which is also upbeat on pharmaceutical sales.
- Shares +0.8% premarket.
JNJ Q3 looking good, says Bernstein
Oct 10 2013, 07:57 ET